A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

Trial Profile

A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Bladder cancer; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Cutaneous T cell lymphoma; Glioma; Head and neck cancer; Leukaemia; Lung cancer; Lymphoma; Malignant melanoma; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 06 Dec 2017 Planned End Date changed from 30 Sep 2017 to 30 Jun 2018.
    • 27 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2017, according to ClinicalTrials.gov record.
    • 27 Sep 2013 Planned End Date changed from 1 Oct 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top